Sanofi (SNY) said Wednesday it has closed the sale of a 50% controlling stake of its consumer healthcare business Opella to private equity firm CD&R for net cash proceeds of around 10 billion euros ($11.35 billion).
The healthcare company said it retains a 48.2% stake in Opella, with investment bank Bpifrance holding the remaining 1.8% stake and joining the board.
Sanofi said it is now a "pure-play biopharma" after the divestment.
The company's shares were up 1.8% in recent trading on Wednesday.
Price: 54.71, Change: +0.99, Percent Change: +1.84
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.